[go: up one dir, main page]

PL2857023T3 - Zastosowanie odiparcilu w leczeniu mukopolisacharydozy - Google Patents

Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Info

Publication number
PL2857023T3
PL2857023T3 PL14187588.0T PL14187588T PL2857023T3 PL 2857023 T3 PL2857023 T3 PL 2857023T3 PL 14187588 T PL14187588 T PL 14187588T PL 2857023 T3 PL2857023 T3 PL 2857023T3
Authority
PL
Poland
Prior art keywords
odiparcil
mucopolysaccharidosis
treatment
Prior art date
Application number
PL14187588.0T
Other languages
English (en)
Inventor
Philippe Masson
Jean-Louis Junien
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2857023T3 publication Critical patent/PL2857023T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
PL14187588.0T 2013-10-04 2014-10-03 Zastosowanie odiparcilu w leczeniu mukopolisacharydozy PL2857023T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1359657A FR3011468B1 (fr) 2013-10-04 2013-10-04 Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose

Publications (1)

Publication Number Publication Date
PL2857023T3 true PL2857023T3 (pl) 2016-09-30

Family

ID=49876835

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16159903T PL3047851T3 (pl) 2013-10-04 2014-10-03 Zastosowanie odiparcilu w leczeniu mukopolisacharydozy
PL14187588.0T PL2857023T3 (pl) 2013-10-04 2014-10-03 Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16159903T PL3047851T3 (pl) 2013-10-04 2014-10-03 Zastosowanie odiparcilu w leczeniu mukopolisacharydozy

Country Status (27)

Country Link
US (1) US9561246B2 (pl)
EP (2) EP3047851B1 (pl)
JP (2) JP6412927B2 (pl)
KR (2) KR102328103B1 (pl)
CN (2) CN109999049B (pl)
AU (1) AU2014330977B2 (pl)
BR (1) BR112016007306B1 (pl)
CA (1) CA2925567C (pl)
CY (2) CY1117740T1 (pl)
DK (2) DK3047851T3 (pl)
EA (1) EA029370B1 (pl)
ES (2) ES2633806T3 (pl)
FR (1) FR3011468B1 (pl)
HR (2) HRP20160811T1 (pl)
HU (2) HUE036306T2 (pl)
IL (1) IL244829A0 (pl)
MA (1) MA38931B1 (pl)
MX (1) MX362596B (pl)
MY (1) MY184721A (pl)
PH (1) PH12016500541A1 (pl)
PL (2) PL3047851T3 (pl)
PT (2) PT2857023T (pl)
RS (2) RS56235B1 (pl)
SI (2) SI2857023T1 (pl)
TN (1) TN2016000111A1 (pl)
UA (1) UA117934C2 (pl)
WO (1) WO2015049471A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982288B2 (en) * 2014-04-30 2018-05-29 The Nemours Foundation Mucopolysaccharidosis IVA/VII screening and treatment method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2024476C (en) * 1989-09-22 1999-10-12 Soth Samreth Benzopyranone-.beta.-d-thioxylosides their method of preparation and their use in therapy
US6866844B2 (en) * 2002-11-07 2005-03-15 Biomarin Pharmaceutical Inc. Precursor N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
GB0400812D0 (en) * 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
AU2005295730A1 (en) * 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
FR2903698B1 (fr) * 2006-07-13 2009-01-30 Fournier S A Sa Lab Nouveaux derives de 5-thioxylopyranose.
MX2013000324A (es) * 2010-06-25 2013-02-01 Shire Human Genetic Therapies Tratamiento del sindrome de sanfilippo tipo b.

Also Published As

Publication number Publication date
US20150099789A1 (en) 2015-04-09
KR102345244B1 (ko) 2021-12-30
CN105636597B (zh) 2019-02-15
RS56235B1 (sr) 2017-11-30
BR112016007306B1 (pt) 2022-09-06
CN109999049A (zh) 2019-07-12
EP3047851A1 (fr) 2016-07-27
DK2857023T3 (en) 2016-07-25
EP2857023A1 (fr) 2015-04-08
JP2016531888A (ja) 2016-10-13
EP2857023B1 (fr) 2016-04-20
CA2925567C (fr) 2021-10-05
EA201690709A1 (ru) 2016-07-29
PT2857023T (pt) 2016-07-11
SI3047851T1 (sl) 2017-10-30
CY1117740T1 (el) 2017-05-17
MX2016004333A (es) 2016-11-10
DK2857023T5 (en) 2016-08-29
TN2016000111A1 (fr) 2017-07-05
PT3047851T (pt) 2017-07-20
CY1119212T1 (el) 2018-02-14
AU2014330977A1 (en) 2016-05-19
JP2018162330A (ja) 2018-10-18
MA38931B1 (fr) 2018-09-28
KR20160058119A (ko) 2016-05-24
FR3011468B1 (fr) 2015-12-04
US9561246B2 (en) 2017-02-07
WO2015049471A1 (fr) 2015-04-09
KR102328103B1 (ko) 2021-11-17
AU2014330977B2 (en) 2019-10-03
PL3047851T3 (pl) 2017-10-31
RS54907B1 (sr) 2016-10-31
MY184721A (en) 2021-04-19
ES2633806T3 (es) 2017-09-25
HUE027787T2 (en) 2016-10-28
CN105636597A (zh) 2016-06-01
HUE036306T2 (hu) 2018-06-28
EP3047851B1 (fr) 2017-06-14
UA117934C2 (uk) 2018-10-25
CA2925567A1 (fr) 2015-04-09
FR3011468A1 (fr) 2015-04-10
JP6412927B2 (ja) 2018-10-24
JP6545334B2 (ja) 2019-07-17
MX362596B (es) 2019-01-25
EA029370B1 (ru) 2018-03-30
SI2857023T1 (sl) 2016-08-31
DK3047851T3 (en) 2017-09-18
KR20210119562A (ko) 2021-10-05
HRP20160811T1 (hr) 2016-09-23
PH12016500541A1 (en) 2016-06-13
IL244829A0 (en) 2016-05-31
ES2578161T3 (es) 2016-07-21
CN109999049B (zh) 2022-01-25
BR112016007306A2 (pt) 2017-09-12
MA38931A1 (fr) 2018-04-30
HRP20171305T1 (hr) 2017-10-20
HK1209033A1 (zh) 2016-06-30

Similar Documents

Publication Publication Date Title
IL246239A0 (en) Bicyclic heterocyclic compounds and their uses in healing
GB201320729D0 (en) Therapeutic compounds and their use
LT3542798T (lt) Aceklidinas, skirtas panaudoti gydant presbiopiją
IL246221A0 (en) Endazoles and their uses
SG11201602838UA (en) Safe socket and use thereof
GB201305277D0 (en) Novel combination and use
GB201311361D0 (en) Compounds and their therapeutic use
GB2515865B (en) Use of galactooligosaccharides in therapy
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
GB201304872D0 (en) Treatment
IL245272B (en) pif-transfected cells and methods of use
GB201307989D0 (en) Novel combinations and use
GB201308736D0 (en) Compounds and their therapeutic use
GB201308753D0 (en) Compounds and their use in therapy
LT3024825T (lt) Imidazolo karboksamidai ir jų panaudojimas kaip faah inhibitorių
GB201304038D0 (en) Treated cells and therapeutic uses
GB201307310D0 (en) Treatment
PT3047851T (pt) Utilização de odiparcil no tratamento de uma mucopolissacaridose
GB201308217D0 (en) Compounds and their use in therapy
GB201309498D0 (en) Novel diagnosis and therapy
GB2525530B (en) Treatment of hard surfaces
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201307677D0 (en) Compounds and their therapeutic use
GB201308539D0 (en) Liquid treatment